52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Saxagliptin is a new investigational medication being developed for treatment of type 2
diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in
addition to metformin and compare to sulphonylurea in addition with metformin.